Fig. 3From: Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patientsOverall survival of plasmablastic lymphoma patients showing a significant adverse impact of age >50Â years (a) and lymph node involvement (b). Patients who presented with Ann Arbor stage III or IV disease had worse overall (c) and event-free survival (d) compared to patients who presented with stage I or IIBack to article page